Latest Insider Transactions at 23and Me Holding Co. (ME)
This section provides a real-time view of insider transactions for 23and Me Holding Co. (ME). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of 23andMe Holding Co. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of 23andMe Holding Co.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Nov 20
2023
|
William G Richards Head of Therapeutics Discovery |
SELL
Payment of exercise price or tax liability
|
Direct |
5,695
-0.85%
|
$0
$0.91 P/Share
|
|
Nov 16
2023
|
Kathy L Hibbs Chief Administrative Officer |
SELL
Open market or private sale
|
Direct |
38,548
-2.91%
|
$0
$0.77 P/Share
|
|
Nov 16
2023
|
Kathy L Hibbs Chief Administrative Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
38,548
+2.83%
|
$0
$0.42 P/Share
|
|
Nov 02
2023
|
Kathy L Hibbs Chief Administrative Officer |
SELL
Open market or private sale
|
Direct |
38,548
-2.91%
|
$0
$0.87 P/Share
|
|
Nov 02
2023
|
Kathy L Hibbs Chief Administrative Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
38,548
+2.83%
|
$0
$0.42 P/Share
|
|
Oct 19
2023
|
Kathy L Hibbs Chief Administrative Officer |
SELL
Open market or private sale
|
Direct |
38,548
-2.91%
|
$0
$0.81 P/Share
|
|
Oct 19
2023
|
Kathy L Hibbs Chief Administrative Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
38,548
+2.83%
|
$0
$0.42 P/Share
|
|
Oct 05
2023
|
Kathy L Hibbs Chief Administrative Officer |
SELL
Open market or private sale
|
Direct |
38,548
-2.91%
|
$0
$0.84 P/Share
|
|
Oct 05
2023
|
Kathy L Hibbs Chief Administrative Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
38,548
+2.83%
|
$0
$0.42 P/Share
|
|
Sep 21
2023
|
Kathy L Hibbs Chief Administrative Officer |
SELL
Open market or private sale
|
Direct |
38,548
-2.91%
|
$38,548
$1.0 P/Share
|
|
Sep 21
2023
|
Kathy L Hibbs Chief Administrative Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
38,548
+2.83%
|
$0
$0.42 P/Share
|
|
Sep 15
2023
|
Kathy L Hibbs Chief Administrative Officer |
BUY
Grant, award, or other acquisition
|
Direct |
1,025,992
+44.4%
|
-
|
|
Sep 15
2023
|
William G Richards Head of Therapeutics Discovery |
BUY
Grant, award, or other acquisition
|
Direct |
459,691
+26.48%
|
-
|
|
Sep 15
2023
|
Joseph Anthony Selsavage Interim CEO, CFO & CAO |
BUY
Grant, award, or other acquisition
|
Direct |
1,025,992
+43.69%
|
-
|
|
Sep 07
2023
|
Kathy L Hibbs Chief Administrative Officer |
SELL
Open market or private sale
|
Direct |
40,894
-13.64%
|
$40,894
$1.06 P/Share
|
|
Sep 07
2023
|
Kathy L Hibbs Chief Administrative Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
40,894
+12.0%
|
$0
$0.42 P/Share
|
|
Sep 06
2023
|
Patrick S Chung Director |
BUY
Grant, award, or other acquisition
|
Direct |
188,387
+25.8%
|
$0
$0.55 P/Share
|
|
Sep 06
2023
|
Neal Mohan Director |
BUY
Grant, award, or other acquisition
|
Direct |
154,997
+38.67%
|
-
|
|
Sep 06
2023
|
Rice Valerie Md Montgomery Director |
BUY
Grant, award, or other acquisition
|
Direct |
190,495
+23.4%
|
$0
$0.55 P/Share
|
|
Sep 06
2023
|
Richard H Scheller Director |
BUY
Grant, award, or other acquisition
|
Direct |
165,088
+41.01%
|
-
|
|
Sep 06
2023
|
Sandra R Md Hernandez Director |
BUY
Grant, award, or other acquisition
|
Direct |
194,363
+22.85%
|
$0
$0.55 P/Share
|
|
Sep 06
2023
|
Peter J. Taylor Director |
BUY
Grant, award, or other acquisition
|
Direct |
137,566
+34.15%
|
-
|
|
Sep 06
2023
|
Roelof Botha Director |
BUY
Grant, award, or other acquisition
|
Direct |
193,379
+36.08%
|
$0
$0.55 P/Share
|
|
Sep 05
2023
|
William G Richards Head of Therapeutics Discovery |
SELL
Open market or private sale
|
Direct |
2,538
-1.19%
|
$2,538
$1.08 P/Share
|
|
Aug 24
2023
|
Kathy L Hibbs Chief Administrative Officer |
SELL
Open market or private sale
|
Direct |
40,894
-13.94%
|
$40,894
$1.05 P/Share
|
|
Aug 24
2023
|
Kathy L Hibbs Chief Administrative Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
40,894
+12.23%
|
$0
$0.42 P/Share
|
|
Aug 20
2023
|
Kathy L Hibbs Chief Administrative Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
4,628
-1.8%
|
$4,628
$1.14 P/Share
|
|
Aug 20
2023
|
William G Richards Head of Therapeutics Discovery |
SELL
Payment of exercise price or tax liability
|
Direct |
8,185
-3.73%
|
$8,185
$1.14 P/Share
|
|
Aug 20
2023
|
Joseph Anthony Selsavage Interim CEO, CFO & CAO |
SELL
Payment of exercise price or tax liability
|
Direct |
6,209
-2.12%
|
$6,209
$1.14 P/Share
|
|
Aug 15
2023
|
Kathy L Hibbs Chief Administrative Officer |
SELL
Open market or private sale
|
Direct |
40,894
-13.72%
|
$40,894
$1.32 P/Share
|
|
Aug 15
2023
|
Kathy L Hibbs Chief Administrative Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
40,894
+12.07%
|
$0
$0.42 P/Share
|
|
Jul 27
2023
|
Kathy L Hibbs Chief Administrative Officer |
SELL
Open market or private sale
|
Direct |
40,894
-13.72%
|
$40,894
$1.89 P/Share
|
|
Jul 27
2023
|
Kathy L Hibbs Chief Administrative Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
40,894
+12.07%
|
$0
$0.42 P/Share
|
|
Jul 13
2023
|
Kathy L Hibbs Chief Administrative Officer |
SELL
Open market or private sale
|
Direct |
40,894
-13.72%
|
$40,894
$1.82 P/Share
|
|
Jul 13
2023
|
Kathy L Hibbs Chief Administrative Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
40,894
+12.07%
|
$0
$0.42 P/Share
|
|
Jun 29
2023
|
Kathy L Hibbs Chief Administrative Officer |
SELL
Open market or private sale
|
Direct |
40,894
-13.72%
|
$40,894
$1.72 P/Share
|
|
Jun 29
2023
|
Kathy L Hibbs Chief Administrative Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
40,894
+12.07%
|
$0
$0.42 P/Share
|
|
Jun 05
2023
|
Kenneth J. Hillan Chief Therapeutics Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
15,347
-6.47%
|
$30,694
$2.08 P/Share
|
|
Jun 05
2023
|
Kenneth J. Hillan Chief Therapeutics Officer |
BUY
Grant, award, or other acquisition
|
Direct |
44,381
+15.76%
|
-
|
|
Jun 05
2023
|
Kathy L Hibbs Chief Administrative Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
15,098
-5.55%
|
$30,196
$2.08 P/Share
|
|
Jun 05
2023
|
Kathy L Hibbs Chief Administrative Officer |
BUY
Grant, award, or other acquisition
|
Direct |
43,659
+13.82%
|
-
|
|
Jun 05
2023
|
Joseph Anthony Selsavage Interim CEO, CFO & CAO |
SELL
Payment of exercise price or tax liability
|
Direct |
13,075
-4.28%
|
$26,150
$2.08 P/Share
|
|
Jun 05
2023
|
Joseph Anthony Selsavage Interim CEO, CFO & CAO |
BUY
Grant, award, or other acquisition
|
Direct |
37,808
+11.0%
|
-
|
|
May 20
2023
|
Kathy L Hibbs Chief Administrative Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
4,628
-1.98%
|
$4,628
$1.94 P/Share
|
|
May 20
2023
|
Kenneth J. Hillan Chief Therapeutics Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
4,628
-2.34%
|
$4,628
$1.94 P/Share
|
|
May 20
2023
|
Joseph Anthony Selsavage Interim CEO, CFO & CAO |
SELL
Payment of exercise price or tax liability
|
Direct |
6,209
-2.26%
|
$6,209
$1.94 P/Share
|
|
Feb 20
2023
|
Kathy L Hibbs Chief Administrative Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
5,457
-2.31%
|
$10,914
$2.87 P/Share
|
|
Feb 20
2023
|
Joseph Anthony Selsavage Interim CEO, CFO & CAO |
SELL
Payment of exercise price or tax liability
|
Direct |
7,321
-2.64%
|
$14,642
$2.87 P/Share
|
|
Feb 20
2023
|
Kenneth J. Hillan Chief Therapeutics Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
5,457
-2.77%
|
$10,914
$2.87 P/Share
|
|
Dec 05
2022
|
Kathy L Hibbs Chief Administrative Officer |
SELL
Open market or private sale
|
Direct |
26,259
-10.02%
|
$78,777
$3.25 P/Share
|